{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Healthy+Volunteers.&page=31",
    "query": {
      "condition": "Healthy Volunteers.",
      "page": 31
    },
    "page_size": 10
  },
  "pagination": {
    "page": 31,
    "page_size": 10,
    "total_count": 7030,
    "total_pages": 703,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Healthy+Volunteers.&page=32&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Healthy+Volunteers.&page=30&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-18T20:25:34.900Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01935960",
      "title": "Retinoid 9cUAB30 in Preventing Cancer in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subject"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Retinoid 9cUAB30",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 40,
      "start_date": "2013-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-12-23",
      "last_synced_at": "2026-11-18T20:25:34.900Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Iowa City, Iowa • Madison, Wisconsin",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01935960"
    },
    {
      "nct_id": "NCT02447120",
      "title": "Topcon 3D OCT-1 Maestro Reference Database Study II",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "3D OCT-1 Maestro",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Topcon Medical Systems, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 504,
      "start_date": "2015-05",
      "completion_date": "2015-10",
      "has_results": false,
      "last_update_posted_date": "2022-06-08",
      "last_synced_at": "2026-11-18T20:25:34.900Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • Fullerton, California • Livermore, California + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Livermore",
          "state": "California"
        },
        {
          "city": "Pomona",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02447120"
    },
    {
      "nct_id": "NCT04072146",
      "title": "Evaluating Relative Bioavailability of OC-01 (Varenicline) Nasal Spray as Compared to Orally Administered Varenicline",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subjects"
      ],
      "interventions": [
        {
          "name": "Vaenicline oral tablet 1 mg, then OC-01 (varenicline solution) nasal spray 0.12 mg",
          "type": "DRUG"
        },
        {
          "name": "OC-01 (varenicline solution) nasal spray 0.12 mg then Varenicline oral tablet 1 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oyster Point Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 22,
      "start_date": "2019-08-26",
      "completion_date": "2019-11-15",
      "has_results": true,
      "last_update_posted_date": "2022-05-23",
      "last_synced_at": "2026-11-18T20:25:34.900Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04072146"
    },
    {
      "nct_id": "NCT01147588",
      "title": "Study Evaluating Effect of Esomeprazole, Omeprazole or Lansoprazole on the Pharmacodynamics (PD) and Pharmacokinetics (PK) of Clopidogrel",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "lansoprazole",
          "type": "DRUG"
        },
        {
          "name": "omeprazole",
          "type": "DRUG"
        },
        {
          "name": "esomeprazole",
          "type": "DRUG"
        },
        {
          "name": "clopidogrel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 149,
      "start_date": "2010-05",
      "completion_date": "2011-05",
      "has_results": false,
      "last_update_posted_date": "2011-06-28",
      "last_synced_at": "2026-11-18T20:25:34.900Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01147588"
    },
    {
      "nct_id": "NCT02242903",
      "title": "A Study of LY3079514 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "LY3079514",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 48,
      "start_date": "2014-10",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2018-10-04",
      "last_synced_at": "2026-11-18T20:25:34.900Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02242903"
    },
    {
      "nct_id": "NCT01675973",
      "title": "A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Severe Renal Impairment"
      ],
      "interventions": [
        {
          "name": "RANEXA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 4,
      "start_date": "2012-07",
      "completion_date": "2012-08",
      "has_results": false,
      "last_update_posted_date": "2012-12-06",
      "last_synced_at": "2026-11-18T20:25:34.900Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01675973"
    },
    {
      "nct_id": "NCT00648180",
      "title": "Food Study of Doxycycline Monohydrate Tablets 100 mg and Adoxa Tablets 100 mg",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Doxycycline Monohydrate Tablets 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Adoxa Tablets 100 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mylan Pharmaceuticals Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2005-07",
      "completion_date": "2005-08",
      "has_results": false,
      "last_update_posted_date": "2024-04-24",
      "last_synced_at": "2026-11-18T20:25:34.900Z",
      "location_count": 1,
      "location_summary": "Morgantown, West Virginia",
      "locations": [
        {
          "city": "Morgantown",
          "state": "West Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00648180"
    },
    {
      "nct_id": "NCT04077879",
      "title": "Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1617 in Healthy Adult Non-Asian and Japanese Subjects Including Assessment of a Food Effect",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "ASP1617",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 97,
      "start_date": "2019-09-19",
      "completion_date": "2021-06-12",
      "has_results": false,
      "last_update_posted_date": "2024-10-23",
      "last_synced_at": "2026-11-18T20:25:34.900Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04077879"
    },
    {
      "nct_id": "NCT04503603",
      "title": "A Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lanadelumab Administered Intravenously in Healthy Adult Volunteer Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Lanadelumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "19 Years to 55 Years"
      },
      "enrollment_count": 12,
      "start_date": "2020-08-10",
      "completion_date": "2020-12-23",
      "has_results": true,
      "last_update_posted_date": "2022-03-07",
      "last_synced_at": "2026-11-18T20:25:34.900Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04503603"
    },
    {
      "nct_id": "NCT05547503",
      "title": "Phase I Single Ascending Dose and Multiple Ascending Doses of Oral AFA-281 in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pain, Neuropathic",
        "Pain, Inflammatory"
      ],
      "interventions": [
        {
          "name": "AFA-281",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Afasci Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 64,
      "start_date": "2023-04-11",
      "completion_date": "2025-05-14",
      "has_results": false,
      "last_update_posted_date": "2025-10-21",
      "last_synced_at": "2026-11-18T20:25:34.900Z",
      "location_count": 1,
      "location_summary": "Los Alamitos, California",
      "locations": [
        {
          "city": "Los Alamitos",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05547503"
    }
  ]
}